ReviewGlobal heart2026
Are Current Lipid Guidelines Adequate for South Asian Patients? A Narrative Review.
Review in Global heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
South Asians, who account for nearly one quarter of the world's population, experience a disproportionately high burden of atherosclerotic cardiovascular disease (ASCVD), often presenting 5-10 years earlier than European populations. This review evaluates whether contemporary lipid-management frameworks adequately address cardiovascular risk in South Asians. South Asians exhibit a distinct lipid phenotype characterised by elevated apolipoprotein B (ApoB), hypertriglyceridaemia, reduced HDL-cholesterol (HDL-C), increased small dense LDL (sdLDL) particles, and a high prevalence of elevated lipoprotein(a) (Lp(a)), features that are incompletely captured by conventional LDL-cholesterol (LDL-C)-based approaches. Existing cardiovascular risk tools show variable performance in South Asian populations, while contemporary guidelines differ substantially in risk assessment, LDL-cholesterol targets, incorporation of risk enhancers, and use of coronary artery calcium (CAC) scoring. Although recent guideline updates increasingly acknowledge South Asian ethnicity as a risk modifier, important gaps in calibration and implementation remain. Greater harmonisation of recommendations and validation of South Asian-specific risk assessment strategies are needed to improve cardiovascular prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.